Premium
Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy
Author(s) -
Iranifar Elmira,
Seresht Banafsheh Mirzaei,
Momeni Fatemeh,
Fadaei Elyas,
Mehr Maysam Havasi,
Ebrahimi Zahra,
Rahmati Majid,
Kharazinejad Ebrahim,
Mirzaei Hamed
Publication year - 2019
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.27214
Subject(s) - microvesicles , microrna , disease , epigenetics , pathogenesis , biology , nanocarriers , exosome , bioinformatics , computational biology , medicine , immunology , gene , genetics , pharmacology , drug , pathology
Exosomes are biological nanocarriers which could be involved in a variety of basic physiological events. They exert their effects via targeting their cargos (i.e., DNAs, messenger RNAs, microRNAs [miRNAs], and proteins) to host cells, which led to change behaviors of recipient cells. One of the important aspects of exosomes is the roles of them in disease conditions. Increasing evidence indicated that exosomes are one of the main players in Alzheimer’s disease (AD) pathogenesis. Hence, it seems that these nanocarriers could be used as diagnostic and therapeutic biomarkers in AD treatment. Another important player in AD pathogenesis is miRNA. MiRNAs are short noncoding RNAs which exert their effects as epigenetic regulators. These molecules involved in different stages of AD. Therefore, miRNAs could be used as prognostic, diagnostic, and therapeutic biomarkers in AD. Here, we summarized various roles of exosomes and application of them in AD pathogenesis. Moreover, we highlighted the utilization of miRNAs as a therapeutic option in AD therapy.